Actively Recruiting

Phase 3
All Genders
ID06911424

A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis

Led by Baxis Pharmaceuticals, Inc. · Updated on 2026-03-17

400

Participants Needed

38

Research Sites

1 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and safety of fusidic acid 1% eye drops compared to a placebo for treating bacterial conjunctivitis in both adults and children. This Phase 3 clinical trial aims to show that fusidic acid 1% is superior to placebo in curing bacterial conjunctivitis and to further confirm its safety when applied topically to the eyes. Participants will be randomly assigned to one of two groups: one group will apply one drop of fusidic acid 1% in each eye twice daily for seven days, and the other group will use a placebo eye drop with the same schedule. The doses are ideally spaced about 12 hours apart, but the twice-daily application schedule is prioritized over exact timing. During the study, participants will be assessed for clinical cure and microbial eradication at Day 4 and Day 8 visits. Researchers will monitor safety and treatment effects through these evaluations and by tracking any adverse events. The total participation duration covers at least the seven days of treatment plus follow-up assessments, helping establish both effectiveness and safety profiles for the treatment.

CONDITIONS

Brief Title

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of suspected bacterial conjunctivitis in at least one eye with purulent or mucopurulent discharge and a grade 2 on the modified Validated Bulbar Redness conjunctival redness scale
  • No ocular treatment for conjunctivitis other than eyelid hygiene within 14 days before Visit 1
  • Negative viral conjunctivitis test in both eyes
  • Willing to stop using eye/eyelid cosmetics during study participation
  • Willing to stop using contact lenses during study participation
  • Able and willing to provide informed consent and comply with study requirements
  • Not currently pregnant or breastfeeding; if sexually active, agrees to use approved contraception during the study
Not Eligible

You will not qualify if you...

  • Signs, symptoms, or diagnosis of fungal, protozoal, or viral eye infection within 30 days before Visit 1
  • Bacterial conjunctivitis symptoms for more than 48 hours before Visit 1
  • Need for non-study topical ocular medication or systemic medications disallowed by the protocol before Visit 1
  • Abnormal ocular anatomy or eye disease/disorder specified as ineligible in the protocol
  • Known intolerance, sensitivity, or allergy to study medications or their components
  • Participation in another clinical trial within 30 days or use of another experimental drug within 90 days before Visit 1
  • Family or household member enrolled in this study
  • Any condition that may impact safety or study outcomes as judged by the investigator
  • Employment or immediate family relation to an employee involved in the study conduct at the study site

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 7 days

Participants instill one drop of study medication per eye twice a day for 7 days to treat suspected bacterial conjunctivitis.

2 visits (Day 4 and Day 8, in-person)

Trial Site Locations

Total: 38 locations

1

Baxis Site 04

Little Rock, Arkansas, United States, 72205

Actively Recruiting

2

Baxis Site 24

Huntington Beach, California, United States, 92647

Withdrawn

3

Baxis Site 19

La Jolla, California, United States, 92037

Actively Recruiting

4

Baxis Site 39

Long Beach, California, United States, 90813

Actively Recruiting

5

Baxis Site 31

Los Angeles, California, United States, 90020

Actively Recruiting

6

Baxis Site 38

Los Angeles, California, United States, 90048

Actively Recruiting

7

Baxis Site 20

Sherman Oaks, California, United States, 91423

Terminated

8

Baxis Site 34

Delray Beach, Florida, United States, 33484

Actively Recruiting

9

Baxis Site 22

Doral, Florida, United States, 33172

Terminated

10

Baxis Site 11

Lake Worth, Florida, United States, 33460

Actively Recruiting

11

Baxis Site 37

Largo, Florida, United States, 33773

Actively Recruiting

12

Baxis Site 27

Lutz, Florida, United States, 33549

Actively Recruiting

13

Baxis Site 01

Miami, Florida, United States, 33155

Actively Recruiting

14

Baxis Site 03

Miami, Florida, United States, 33176

Terminated

15

Baxis Site 13

Miami Beach, Florida, United States, 33140

Terminated

16

Baxis Site 28

Miami Lakes, Florida, United States, 33014

Actively Recruiting

17

Baxis Site 29

Palm Springs, Florida, United States, 33461

Actively Recruiting

18

Baxis Site 10

Tampa, Florida, United States, 33613

Actively Recruiting

19

Baxis Site 35

Union City, Georgia, United States, 30291

Actively Recruiting

20

Baxis Site 15

Idaho Falls, Idaho, United States, 83404

Terminated

21

Baxis Site 06

Orland Park, Illinois, United States, 60462

Actively Recruiting

22

Baxis Site 26

Columbia, Maryland, United States, 21045

Withdrawn

23

Baxis Site 21

North Las Vegas, Nevada, United States, 89030

Terminated

24

Baxis Site 23

Babylon, New York, United States, 11702

Withdrawn

25

Baxis Site 05

Mount Airy, North Carolina, United States, 27030

Terminated

26

Baxis Site 25

Tulsa, Oklahoma, United States, 74133

Withdrawn

27

Baxis Site 30

Gresham, Oregon, United States, 97030

Actively Recruiting

28

Baxis Site 09

Pittsburgh, Pennsylvania, United States, 15227

Withdrawn

29

Baxis Site 12

Charleston, South Carolina, United States, 29414

Actively Recruiting

30

Baxis Site 33

Greenville, South Carolina, United States, 29607

Actively Recruiting

31

Baxis Site 08

Edinburg, Texas, United States, 78539

Actively Recruiting

32

Baxis Site 02

Humble, Texas, United States, 77338

Terminated

33

Baxis Site 14

Kingwood, Texas, United States, 77345

Terminated

34

Baxis Site 36

Mission, Texas, United States, 78572

Actively Recruiting

35

Baxis Site 17

Layton, Utah, United States, 84041

Terminated

36

Baxis Site 18

Layton, Utah, United States, 84041

Terminated

37

Baxis Site 16

West Valley City, Utah, United States, 84120

Withdrawn

38

Baxis Site 32

Charlottesville, Virginia, United States, 22902

Actively Recruiting

Loading map...

Research Team

D

Director of Clinical Operations

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here